Article
Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) - 1 Jul 2023
Xu Yiquan, Yan Jingjing, Zhou Chengzhi, Wu Lin, Wang Haibo, Zhao Jun, Zhou Maolin, Wang Jingyi, Zheng Xinlong, Zhang Longfeng, Jiang Kan, Zheng Xiaobin, Miao Qian, Wu Shiwen, Zou Zihua, Lian Rong, He Yuange, Chen Rongrong, Yang Shanshan, Li Yujing, Chen Sihui, Lin Gen
Abstract excerpt
BACKGROUND: Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation generally respond well to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). However, genomic characterisation of de novo EGFR copy number gain (CNG) and its impact on the efficacy of first-line EGFR-TKIs remains unclear. METHODS: This multicenter, retrospective and real-world study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.